



DUB profiler



DUB profiler™

Determine the *selectivity* and *potency* of your DUB inhibitors

Introducing DUB profiler
Compound Screening Service
Single concentration profiling and IC₅₀ analysis

Linking
Ubiquitin Research
TO DRUG DISCOVERY



About DUB^{profiler}

The utility of determining the selectivity of drug discovery lead compounds directed to target classes such as kinases and G protein-coupled receptors (GPCRs) has long been proven. As our understanding of the diverse roles and functions of deubiquitylase (DUB; or deubiquitinase) enzymes develops, it is fuelling an accelerating interest in drug discovery opportunities around members of this family across many therapeutic classes (Singhal, Taylor *et al.* 2008; Hussain, Zhang *et al.* 2009; Cohen and Tcherpakov 2010; Colland 2010).

With DUB^{profiler}, Ubiquigent is ideally placed to support you with your DUB inhibitor selectivity and potency profiling needs. Ubiquigent is located adjacent to both the Protein Ubiquitylation and Protein Phosphorylation Units at the University of Dundee, UK: Both of these units being led by Professor Sir Philip Cohen (Ubiquigent's co-founder) who pioneered the concept, utility and drug discovery application of kinase inhibitor profiling. Further, the operational group at Ubiquigent previously developed and provided kinase profiling services and have engineered DUB^{profiler} with this experience and knowledge of client compound profiling needs in mind.

Please contact us to learn more about our DUB^{profiler} services.

References:

Cohen, P. and M. Tcherpakov (2010). "Will the ubiquitin system furnish as many drug targets as protein kinases?" *Cell* **143(5)**: 686-693.

Colland, F. (2010). "The therapeutic potential of deubiquitinating enzyme inhibitors." *Biochem Soc Trans* **38(Pt 1)**: 137-143.

Hussain, S., Y. Zhang, *et al.* (2009). "DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors." *Cell Cycle* **8(11)**: 1688-1697.

Singhal, S., M. C. Taylor, *et al.* (2008). "Deubiquitylating enzymes and disease." *BMC Biochem* **9 Suppl 1**: S3.



For More Information

If you are interested in DUB^{profiler} or our custom HTS assay development drug discovery services, please email us at services@ubiquigent.com



www.ubiquigent.com

DUB^{profiler} Process

WHAT YOU DO:

- Send us your compound(s).
- Request single concentration profiling and/or IC₅₀ analysis (electronic submission).

WHAT WE DO:

- Determine the selectivity and specificity of your deubiquitinase (DUB) inhibitor lead compound(s).
- Electronically report fully quality controlled data to you (single concentration % activities or IC₅₀s).

SERVICE FEATURES:

- 21 DUBs on the panel and expanding.
- Ubiquitin-rhodamine(110)-glycine substrate based-assay.
- Any scale and combination of screening; compound(s) vs. DUB(s).
- Simple, flexible and rapid service ordering procedure.
- Compound autofluorescence and product signal modulation control data provided.
- 2 week service cycle.
- Multiple families represented.

